Inquiry Basket
Loading ......
The natriuretic peptides—proBNP (pro-brain natriuretic peptide), BNP (brain natriuretic peptide), and NT-proBNP (N-terminal pro-brain natriuretic peptide)—have emerged as essential biomarkers in cardiovascular diagnostics. Among these, BNP and NT-proBNP are particularly valuable due to their established utility in diagnosing and stratifying heart failure. These peptides play vital roles in modulating cardiovascular homeostasis through natriuretic, diuretic, and vasodilatory effects.
Fig. 1 The cleavage of proBNP.
(Kim YS, et al. Appl Microbiol Biotechnol. 2019)
NT-proBNP is widely used in clinical practice due to its superior stability and longer half-life compared to BNP. Elevated NT-proBNP levels are strongly associated with heart failure and can be used to distinguish heart failure from other causes of dyspnea. However, there is a "gray zone" for both NT-proBNP and BNP levels in the diagnosis of HF in which sensitivity and specificity are lower and the diagnosis of HF is less certain (Table 1). Thus, this gray zone is an area where additional biomarkers are needed to assist with diagnosis.
Table 1 Rule in, rule out, and gray zone for BNP and NT-proBNP.
| Diagnosis | BNP (pg/mL) | NT-proBNP (pg/mL) | ||
| Any age | <50 years | 50–74 years | ≥75 years | |
| Rule out | <100 | <300 | <300 | <300 |
| Gray Zone | 100–500 | 300–450 | 300–900 | 300–1,800 |
| Rule in | >500 | >450 | >900 | >1,800 |
BNP/NT-proBNP can be used as predictors of the long‐term prognosis in patients with heart failure. Elevated NT-proBNP levels correlate with increased mortality, higher hospitalization rates, and worse clinical outcomes across both acute and chronic HF patients.
Serial measurements of NT-proBNP can track treatment effectiveness, with a reduction in peptide levels often correlating with clinical improvement, such as improved functional class or reduced hospitalization. On the contrary, persistently elevated levels may signal inadequate therapy or worsening disease.
Fig. 2 Pathway for using BNP and NT-proBNP in diagnosis, prognosis and management of acute heart failure.
(Wettersten N. Int J Heart Fail. 2021)
Creative Diagnostics offers a range of high-quality antibodies for BNP and NT-proBNP, suitable for both raw material and research applications. These antibodies are meticulously validated for use in ELISA, LFIA, CLIA, Western blot and other research techniques. With excellent specificity and sensitivity, these products are trusted tools for developing diagnostic assays methods and research use.
Fig. 3 ELISA standard curve of NT-proBNP antibody pair, R2>0.99.
(Cat. No. DCABY-4587 - DMABB-JX734).
Fig. 4 Consistency analysis of assigned serum samples (NT-proBNP Conc. range 259-2654 pg/mL), R2 > 0.95.
(Cat. No. DCABY-4587 - DMABB-JX734).
Fig. 5 Consistency analysis of assigned serum samples (NT-proBNP Conc. range 0-35000 pg/mL), R2 > 0.99.
(Cat. No. DMABB-JX690 - DMABB-JX691).
Fig. 6 Consistency analysis of assigned serum samples (NT-proBNP Conc. range 0-500 pg/mL), R2 > 0.95.
(Cat. No. DMABB-JX690 - DMABB-JX691).
Fig. 7 Western blot analysis of BNP on different lysates with BNP Rabbit mAb at 1:1000 dilution.
(Cat. No. DMABB-JX747)
Fig. 8 Immunofluorescence analysis of U2OS cells using BNP Rabbit pAb at dilution of 1:200.
(Cat. No. DPABB-JX325)
Fig 9. Immunohistochemistry of paraffin-embedded human brain using BNP mouse mAb in 30μg/ml dilute concentrations.
(Cat. No. DMABB-JX749)
References
| Feline NT-proBNP Antibodies | ||||
| Cat. No. | Product Name | Application | Pair Info. | |
| DMABB-JX110 | Mouse Anti-Feline NT-proBNP monoclonal antibody, clone B8160 | ELISA, LFIA | DMABB-JX110 - DMABB-JX111 | Inquiry |
| DMABB-JX111 | Mouse Anti-Feline NT-proBNP monoclonal antibody, clone B8171 | ELISA, LFIA | Inquiry | |
| Canine NT-proBNP Antibodies | ||||
| Cat. No. | Product Name | Application | Pair Info. | |
| CABT-CS013 | Mouse Anti-Canine NT-proBNP Monoclonal antibody, clone DbOU91 | ELISA | CABT-CS013 - CABT-CS012 | Inquiry |
| CABT-CS012 | Mouse Anti-Canine NT-proBNP Monoclonal antibody, clone DbOU90 | ELISA | Inquiry | |
Loading ......
